Bortero

Bortero

bortezomib

Manufacturer:

Amarox
Concise Prescribing Info
Contents
Bortezomib
Indications/Uses
Multiple myeloma patients who have received at least 1 prior therapy & have demonstrated disease progression on the last therapy. Patients w/ mantle cell lymphoma who have received at least 1 prior therapy.
Dosage/Direction for Use
IV 1.3 mg/m2 as 3-5 sec bolus inj twice wkly for 2 wk (day 1, 4, 8 & 11) followed by 10-day rest period (day 12-21).
Special Precautions
Patients w/ a confirmed complete response is recommended to receive 2 additional cycles beyond a confirmation. Responding patients who do not achieve a complete remission receive a total of 8 cycles of therapy.
ATC Classification
L01XX32 - bortezomib ; Belongs to the class of other antineoplastic agents. Used in the treatment of cancer.
Presentation/Packing
Form
Bortero lyo powd for inj 3.5 mg
Packing/Price
1's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in